Journal of Applied Hematology

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 13  |  Issue : 2  |  Page : 91--94

Immune tolerance induction experience from a single institute in the United Arab Emirates


Najam Ahmed Muhammad Ahmed Awan, Layla Ali Eisa Mohamed Alreyami, Asia Ahmad Abdallah Al Mulla, Majed Mohammed Alremeithi, Muhammad Faisal Khanani 
 Department of Hematology Oncology, Tawam Hospital, Al Ain, UAE

Correspondence Address:
Dr. Najam Ahmed Muhammad Ahmed Awan
Department of Hematology Oncology, Tawam Hospital, Al Ain
UAE

BACKGROUND: Immune tolerance induction (ITI) is the gold standard approach for eradicating inhibitors and increasing patient tolerance to factor VIII. The success rate of ITI may vary depending on patient variables and factors relating to the pattern of treatment for the induction of immune tolerance. Children with recently diagnosed inhibitors are the best candidates for ITI, and those with favourable expected results should be offered ITI as soon as inhibitors are identified. Recombinant factor VIII Fc fusion protein has proved a therapeutic advantage in patients with high factor VIII inhibitor titers AIMS AND OBJECTIVES: To evaluate the clinical characteristics and outcomes of ten hemophilic pediatric patients who underwent ITI therapies to eliminate FVIII inhibitors at Tawam Hospital, UAE MATERIALS AND METHODS: The data of ten hemophilia A children aged 2–7 years with high inhibitor titers who underwent ITI therapy at Tawam Hospital, UAE, were retrospectively collected for this case series. A comparison of bleeds before and after the ITI therapy was also made. Patients with either failed or partially successful primary ITI therapy underwent rescue ITI therapy. Data analysis was performed using SPSS version 26. RESULTS: Full success was achieved in 60% (6/10) of the patients, 10% (1/10) achieved partial success, whereas 30% (3/10) failed the primary ITI therapy. The rescue ITI therapy was successful in 50% (2/4) of the patients and the remaining 50% (2/4) achieved partial success [Table 2]. The rescue ITI was successful in 66% (2/3) of those patients who received Elocta and partially successful in 33% (1/3) CONCLUSION: ITI therapy is the gold standard for the eradication of antibodies against FVIII. The patients with good expected outcomes should be offered ITI as soon as the inhibitors are confirmed. The use of extended half life rFVIIIFc demonstrated therapeutic benefit, particularly in challenging ITI patients with high inhibitor titers


How to cite this article:
Ahmed Awan NA, Mohamed Alreyami LA, Al Mulla AA, Alremeithi MM, Khanani MF. Immune tolerance induction experience from a single institute in the United Arab Emirates.J Appl Hematol 2022;13:91-94


How to cite this URL:
Ahmed Awan NA, Mohamed Alreyami LA, Al Mulla AA, Alremeithi MM, Khanani MF. Immune tolerance induction experience from a single institute in the United Arab Emirates. J Appl Hematol [serial online] 2022 [cited 2022 Aug 19 ];13:91-94
Available from: https://www.jahjournal.org/article.asp?issn=1658-5127;year=2022;volume=13;issue=2;spage=91;epage=94;aulast=Ahmed;type=0